Sugi Predict

Sugi Predict / Compounds / SCHEMBL4485284

SCHEMBL4485284

SCHEMBL4485284

COC(=O)c1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 17/20 0.76
▸ KIT P10721 12/20 0.76
▸ FLT3 P36888 11/20 0.76
▸ AXL P30530 7/20 0.76
▸ HIPK4 Q8NE63 7/20 0.76
▸ CLK4 Q9HAZ1 7/20 0.76
▸ RET P07949 7/20 0.76
▸ FGFR1 P11362 7/20 0.76
▸ FLT1 P17948 7/20 0.76
▸ CSF1R P07333 6/20 0.76
▸ RPS6KB1 P23443 6/20 0.76
▸ PLK4 O00444 6/20 0.76
▸ MAP4K4 O95819 6/20 0.76
▸ CSNK1G2 P78368 6/20 0.76
▸ MAP4K2 Q12851 6/20 0.76
▸ STK3 Q13188 6/20 0.76
▸ ROCK1 Q13464 6/20 0.76
▸ CAMK2G Q13555 6/20 0.76
▸ CAMK2D Q13557 6/20 0.76
▸ NTRK2 Q16620 6/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472448 0.89 KDR (0.80) KDRKITFLT3AXLHIPK4
SCHEMBL232042 0.86 KDR (1.00) KDRKITFLT3AXLHIPK4
SCHEMBL4473073 0.86 KDR (0.77) KDRKITFLT3AXLHIPK4
SCHEMBL4474877 0.85 KDR (0.80) KDRKITFLT3AXLHIPK4
SCHEMBL3531757 0.85 KDR (0.76) KDRKITFLT3AXLHIPK4
SCHEMBL4486611 0.85 KDR (1.00) KDRKITFLT3AXLHIPK4
SCHEMBL4477648 0.84 KDR (1.00) KDRKITFLT3AXLHIPK4
SCHEMBL4477423 0.84 KDR (0.78) KDRKITFLT3AXLHIPK4
SCHEMBL4478814 0.84 KDR (0.78) KDRKITFLT3AXLHIPK4
SCHEMBL4477679 0.83 KDR (0.79) KDRKITFLT3AXLHIPK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885KIT 394/4885FLT3 29/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885KIT 361/4885FLT3 16/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885KIT 394/4885FLT3 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.